Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
- Authors
- Suh, Koung Jin; Cheong, June-Won; Kim, Inho; Kim, Hyeoung-Joon; Shin, Dong-Yeop; Koh, Youngil; Yoon, Sung -Soo; Min, Yoo Hong; Ahn, Jae-Sook; Kim, Yeo-Kyeoung; Lee, Yun-Gyoo; Lee, Jeong-Ok; Bang, Soo-Mee; Mun, Yeung-Chul; Seong, Chu-Myoung; Park, Yong; Kim, Byung-Soo; Hong, Junshik; Park, Jinny; Lee, Jae Hoon; Kim, Sung -Yong; Lee, Hong Ghi
- Issue Date
- 8-Nov-2016
- Publisher
- PUBLIC LIBRARY SCIENCE
- Citation
- PLOS ONE, v.11, no.11
- Journal Title
- PLOS ONE
- Volume
- 11
- Number
- 11
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7672
- DOI
- 10.1371/journal.pone.0166245
- ISSN
- 1932-6203
- Abstract
- Chromosomal translocations are rare in myelodysplastic syndrome (MDS) and their impact on overall survival (OS) and response to hypomethylating agents (HMA) is unknown. The prognostic impact of the revised International Prognostic Scoring System (IPSS-R) and for chromosomal translocations was assessed in 751 patients from the Korea MDS Registry. IPSS-R effectively discriminated patients according to leukaemia evolution risk and OS. We identified 40 patients (5.3%) carrying translocations, 30 (75%) of whom also fulfilled complex karyotype criteria. Translocation presence was associated with a shorter OS (median, 12.0 versus 79.7 months, P < 0.01). Multivariate analysis demonstrated that translocations (hazard ratio [HR] 1.64 [1.06-2.63]; P = 0.03) as well as age, sex, IPSS-R, and CK were independent predictors of OS. In the IPSS-R high and very high risk subgroup (n=260), translocations remained independently associated with OS (HR 1.68 [1.06-2.69], P = 0.03) whereas HMA treatment was not associated with improved survival (median OS, 20.9 versus 21.2 months, P = 0.43). However, translocation carriers exhibited enhanced survival following HMA treatment (median 2.1 versus 12.4 months, P = 0.03). Our data suggest that chromosomal translocation is an independent predictor of adverse outcome and has an additional prognostic value in discriminating patients with MDS having higher risk IPSS-R who could benefit from HMA treatment.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7672)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.